B lymphocytes (B cells) are a subtype of adaptive immune cells responsible primarily for antibody production. Most hematologic malignancies (leukemias, lymphomas, and myeloma) arise from different stages of B-cell development, and many targeted therapies specifically act on B-cell surface markers or signaling pathways.
Below is a clinically focused explanation tailored to oncology pharmacy practice.
B Lymphocytes (B Cells)
1. Definition
B lymphocytes are immune cells that:
- Develop in the bone marrow
- Differentiate into antibody-producing plasma cells
- Provide humoral immunity
They recognize specific antigens using B-cell receptors (BCRs) and produce immunoglobulins (antibodies).
2. Main Functions of B Cells
| Function | Description | Clinical Relevance |
|---|---|---|
| Antibody production | Plasma cells produce immunoglobulins (IgG, IgA, IgM, IgE, IgD) | Dysregulated production → multiple myeloma |
| Antigen presentation | B cells present antigen to T cells via MHC II | Important for immune activation |
| Immune memory | Memory B cells provide long-term immunity | Basis of vaccination |
| Cytokine secretion | Regulate immune responses | May contribute to autoimmune diseases |
3. B-Cell Development
B cells mature through distinct stages, and different cancers originate at each stage.
| Development Stage | Location | Key Markers | Associated Malignancies |
|---|---|---|---|
| Hematopoietic stem cell | Bone marrow | CD34 | Acute leukemias |
| Pro-B cell | Bone marrow | CD19, CD10 | B-ALL |
| Pre-B cell | Bone marrow | CD19, CD10, TdT | B-ALL |
| Immature B cell | Bone marrow | Surface IgM | B-ALL variants |
| Naive mature B cell | Blood/lymph nodes | CD19, CD20 | CLL, SLL |
| Germinal center B cell | Lymph node follicles | CD10, BCL6 | Follicular lymphoma, Burkitt lymphoma |
| Memory B cell | Peripheral lymphoid tissue | CD27 | Some lymphomas |
| Plasma cell | Bone marrow | CD38, CD138 | Multiple myeloma |
4. B-Cell Receptor (BCR) Signaling
The BCR pathway is central to B-cell survival and proliferation, and it is a major therapeutic target in oncology.
Key Signaling Proteins
| Protein | Role | Targeted Drugs |
|---|---|---|
| BTK (Bruton Tyrosine Kinase) | BCR signaling | Ibrutinib, Acalabrutinib, Zanubrutinib |
| PI3K | Cell survival | Idelalisib, Copanlisib |
| SYK | BCR signaling mediator | Fostamatinib (less common) |
| BCL2 | Prevents apoptosis | Venetoclax |
These pathways are dysregulated in many B-cell malignancies.
5. Major B-Cell Surface Markers
These cluster of differentiation (CD) markers help diagnose and treat B-cell cancers.
| Marker | Expression | Clinical Importance |
|---|---|---|
| CD19 | Most B cells | CAR-T target |
| CD20 | Mature B cells | Rituximab target |
| CD22 | Mature B cells | Inotuzumab target |
| CD52 | B and T cells | Alemtuzumab |
| CD79a/b | BCR signaling | Polatuzumab |
| CD38 | Plasma cells | Daratumumab |
| CD138 | Plasma cells | Myeloma marker |
6. Immunoglobulins Produced by B Cells
| Antibody | Function | Oncology Relevance |
|---|---|---|
| IgM | First antibody produced | Elevated in Waldenström macroglobulinemia |
| IgG | Main circulating antibody | Most common monoclonal protein in myeloma |
| IgA | Mucosal immunity | Some myeloma cases |
| IgE | Allergy response | Rare involvement |
| IgD | B-cell receptor component | Rare myeloma subtype |
7. B-Cell Malignancies
Because B cells pass through multiple developmental stages, malignancies arise at different points in maturation.
| Disease | Origin Stage |
|---|---|
| B-cell Acute Lymphoblastic Leukemia (B-ALL) | Immature B cells |
| Chronic Lymphocytic Leukemia (CLL) | Mature naive B cells |
| Follicular Lymphoma | Germinal center B cells |
| Diffuse Large B-Cell Lymphoma | Activated B cells |
| Burkitt Lymphoma | Germinal center B cells |
| Mantle Cell Lymphoma | Naive mantle zone B cells |
| Multiple Myeloma | Plasma cells |
8. Targeted Therapies Against B Cells
Modern oncology heavily targets B cells.
| Target | Drug Examples | Used In |
|---|---|---|
| CD20 | Rituximab, Obinutuzumab | Lymphomas, CLL |
| CD19 | CAR-T therapy | B-ALL, DLBCL |
| CD22 | Inotuzumab | B-ALL |
| BCMA | CAR-T, bispecifics | Multiple myeloma |
| BTK | Ibrutinib | CLL, mantle cell lymphoma |
| BCL2 | Venetoclax | CLL, AML |
9. Why B Cells Are So Important in Hematologic Malignancies
Approximately 85–90% of lymphoid cancers originate from B cells.
Examples include:
This explains why most hematologic oncology drugs target B-cell antigens.
10. Quick Summary
| Feature | B Lymphocytes |
|---|---|
| Origin | Bone marrow |
| Main role | Antibody production |
| Key receptor | B-cell receptor (BCR) |
| Mature form | Plasma cell |
| Key markers | CD19, CD20, CD22 |
| Major cancers | Leukemia, lymphoma, myeloma |
| Major drug targets | CD20, BTK, BCL2, CD19 |